一、产品概述
BMS-582664;丙氨酸布立尼布 是来自Absin品牌的高品质产品,适用于科研实验领域。
更多产品描述请查看优宁维旗下爱必信官网(https://www.absin.cn/brivanib-alaninate/abs813189.html?mk_channel=chemicalbook)
二、产品信息
| 货号 | abs813189 |
| SKU货号 | abs813189-10mg |
| 品牌 | Absin |
| 中文名称 | BMS-582664;丙氨酸布立尼布 |
| 英文名称 | Brivanib alaninate |
| CAS号 | 649735-63-7 |
| 纯度 | >98% |
| 分子量 | 441.46 |
| 可溶性 | Ethanol :82 mg/mL (185.7 mM)
DMSO :82 mg/mL (185.7 mM) |
| 抗原名称 | VEGFR2,Flk1,FGFR1,VEGFR1 |
商品描述
Brivanib Alaninate (BMS-582664)是BMS-540215的前体药物,是一种ATP竞争性的VEGFR2抑制剂,IC50为25 nM。BMS-582664抑制VEGF和FGF刺激的HUVECs 增殖,IC50分别为40 nM 和276 nM。 BMS-582664 (2 μM)作用于VEGF和 bFGF刺激的SK-HEP1细胞和 HepG-2细胞,显著抑制VEGFR-2,FGFR-1,ERK1/2和Akt的磷酸化,而 BMS-582664单独作用于未经刺激的细胞,则对ERK1/2, Akt, VEGFR-2, 和FGFR-1的磷酸化水平没有影响。BMS-582664 抑制 CYP2C19, CYP3A4(BFC) 和 CYP3A4 (BzRes),IC50分别为2.4 μM, 0.51 μM 和 1.6 μM。
In vitro(体外研究)
BMS-582664 inhibits VEGF-stimulated and FGF-stimulated proliferating of HUVECs with IC50 of 40 nM and 276 nM. BMS-582664 (2 μM) significantly inhibits VEGFR2, FGFR1, ERK1/2 and Akt phosphorylation in VEGF- and bFGF-stimulated SK-HEP1 cells and HepG-2 cells, while BMS-582664 alone has little effect on levels of phosphorylated ERK1/2, Akt, VEGFR2, and FGFR1 in nonstimulated cells. BMS-582664 inhibits CYP2C19, CYP3A4(BFC) and CYP3A4 (BzRes) with IC50 of 2.4 μM, 0.51 μM and 1.6 μM, respectively. BMS-582664 exhibits high solid state stability (only 0.3% degradation at 50℃ with desiccant over a period of 12 weeks) and acceptable solution state stability up to pH 6.5.
In vivo(体内研究)
BMS-582664 (50 mg/kg) results in AUC of 136 μM×hr and Cmax of 41 μM in mouse. BMS-582664 (60 mg/kg, orally) is rapidly absorbed with Tmax of 1 hour, a favorable half-life (t1/2) of 2.7 hours and mean residence time (MRT) of 3.6 hours in mouse. BMS-582664 (25 mg/kg) results in AUC of 13.4 μM×hr and Cmax of 6.4 μM in rat. BMS-582664 dose-dependently inhibits the growth of established tumors with tumor growth inhibition of 85% and 97% at dose of 60 mg/kg and 90 mg/kg in H3396 xenografts athymic mice. BMS-582664 inhibits the growth rate of tumors in mice with patient-derived xenograft line 06-0606 by 55% and 13% at dose of 50 mg/kg and 100 mg/kg. BMS-582664 (60 mg/kg, orally) significantly reduces tumor weight at sacrifice, increases apoptosis, reduces microvessel density, inhibits of cell proliferation, and down-regulates cell cycle regulators in mice with patient-derived xenograft line 06-0606. BMS-582664 dose-dependently inhibits the growth of established tumors with tumor growth inhibition of 85% and 97% at dose of 80 mg/kg and 107 mg/kg in a L2987 nonsmall cell lung tumor xenografts assay in athymic mice. BMS-582664 (100 mg/kg) significantly modulates tyrosine kinase receptor 1 (Tie-1), collagen type IV alpha1 (Col4a1), complement component 1, q subcomponent receptor 1 (C1qr1), angiotensin receptor-like 1 (Agtrl1), and vascular endothelial-cadherin (Cdh5) in L2987 nonsmall cell lung tumor xenografts assay in athymic mice. BMS-582664 (100 mg/kg) inhibits the new growth of endothelial cells in two xenografts mouse models, L2987 and HCT116.
三、背景
| 别名 | BMS-582664;丙氨酸布立尼布 |
| CAS号 | 649735-63-7 |
四、制备和贮存
| 保存方式 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
五、产品特点
- 品质保证:经过严格的质量控制,确保产品的高品质和稳定性。
- 高纯度:纯度达到<p>>98%</p>。
六、注意事项
- 本产品仅供科学研究使用,不可用于临床诊断或治疗。
- 请在通风良好的环境下操作,佩戴适当的个人防护装备。
- 如不慎接触皮肤或眼睛,请立即用大量清水冲洗并就医。